Bristol-Myers Squibb (NYSE:BMY) Given Consensus Rating of “Hold” by Brokerages

Bristol-Myers Squibb (NYSE:BMY) has been assigned a consensus rating of “Hold” from the twenty-two research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $58.00.

A number of analysts have commented on the stock. Jefferies Financial Group reduced their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Hedge Funds Weigh In On Bristol-Myers Squibb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at $26,000. Global Wealth Strategies & Associates boosted its stake in shares of Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $49.71 on Friday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a 50-day moving average of $48.71 and a 200-day moving average of $54.77. The firm has a market cap of $101.15 billion, a price-to-earnings ratio of -11.25, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the firm posted ($4.40) EPS. The business’s revenue for the quarter was down 5.6% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.